title: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma.
abstract: BACKGROUND
  MiR-221 and miR-222 (miR-221/222) are frequently up-regulated in various types of human malignancy including glioblastoma. Recent studies have reported that miR-221/222 regulate cell growth and cell cycle progression by targeting p27 and p57. However the underlying mechanism involved in cell survival modulation of miR-221/222 remains elusive.
  
  
  RESULTS
  Here we showed that miR-221/222 inhibited cell apoptosis by targeting pro-apoptotic gene PUMA in human glioma cells. Enforced expression of miR-22/222 induced cell survival whereas knockdown of miR-221/222 rendered cells to apoptosis. Further, miR-221/222 reduced PUMA protein levels by targeting PUMA-3'UTR. Introducing PUMA cDNA without 3'UTR abrogated miR-221/222-induced cell survival. Notably, knockdown of miR-221/222 induces PUMA expression and cell apoptosis and considerably decreases tumor growth in xenograft model. Finally, there was an inverse relationship between PUMA and miR-221/222 expression in glioma tissues.
  
  
  CONCLUSIONS
  To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma intervention.
authors.affiliation: Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Chun-Zhi
authors.initials: CZ
authors.lastname: Zhang
authors.forename: Jun-Xia
authors.initials: JX
authors.lastname: Zhang
authors.forename: An-Ling
authors.initials: AL
authors.lastname: Zhang
authors.forename: Zhen-Dong
authors.initials: ZD
authors.lastname: Shi
authors.forename: Lei
authors.initials: L
authors.lastname: Han
authors.forename: Zhi-Fan
authors.initials: ZF
authors.lastname: Jia
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Yang
authors.forename: Guang-Xiu
authors.initials: GX
authors.lastname: Wang
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
authors.forename: Yong-Ping
authors.initials: YP
authors.lastname: You
authors.forename: Pei-Yu
authors.initials: PY
authors.lastname: Pu
authors.forename: Jin-Quan
authors.initials: JQ
authors.lastname: Cheng
authors.forename: Chun-Sheng
authors.initials: CS
authors.lastname: Kang
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000378:metabolism*; D015152:Blotting, Northern; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000502:physiology; D005260:Female; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D066298:In Vitro Techniques; D051379:Mice; D008819:Mice, Nude; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D041681:NIH 3T3 Cells; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D051017:Apoptosis Regulatory Proteins; D035683:MicroRNAs; D011518:Proto-Oncogene Proteins; C438378:BBC3 protein, human; C525709:MIR221, human; C546122:MIRN221 microRNA, mouse; C525710:MIR222, human; C546123:MIRN222 microRNA, mouse
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80
references.pmid: 16365291
references.citation: Lab Invest. 2010 Feb;90(2):144-55
references.pmid: 20048743
references.citation: Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8
references.pmid: 16039986
references.citation: Cell Death Differ. 2009 Apr;16(4):555-63
references.pmid: 19079139
references.citation: J Biol Chem. 2008 Nov 7;283(45):31079-86
references.pmid: 18790736
references.citation: Science. 2007 Feb 9;315(5813):856-9
references.pmid: 17289999
references.citation: Cancer Res. 2008 Apr 15;68(8):2773-80
references.pmid: 18413744
references.citation: Oncogene. 2006 Apr 20;25(17):2537-45
references.pmid: 16331254
references.citation: Genes Chromosomes Cancer. 2004 Feb;39(2):167-9
references.pmid: 14695998
references.citation: Stem Cells. 2008 Dec;26(12):3027-36
references.pmid: 18802038
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: Cancer Res. 2008 May 1;68(9):3396-404
references.pmid: 18451167
references.citation: Cancer Res. 2005 Aug 15;65(16):7065-70
references.pmid: 16103053
references.citation: EMBO J. 2007 Aug 8;26(15):3699-708
references.pmid: 17627278
references.citation: Mol Cell. 2001 Mar;7(3):673-82
references.pmid: 11463391
references.citation: Cell Death Differ. 2009 Aug;16(8):1135-45
references.pmid: 19300452
references.citation: Mol Cancer Res. 2003 Oct;1(12):882-91
references.pmid: 14573789
references.citation: Oncogene. 2007 Feb 26;26(9):1324-37
references.pmid: 17322918
references.citation: Cancer Res. 2004 Jun 1;64(11):3753-6
references.pmid: 15172979
references.citation: N Engl J Med. 2005 Oct 27;353(17):1768-71
references.pmid: 16251533
references.citation: Clin Cancer Res. 2009 Jun 15;15(12):4009-16
references.pmid: 19509156
references.citation: Oncogene. 2008 Sep 25;27(43):5651-61
references.pmid: 18521080
references.citation: Cell Biochem Funct. 2008 Aug;26(6):692-700
references.pmid: 18636433
references.citation: Methods. 2008 Mar;44(3):229-34
references.pmid: 18314053
references.citation: Brain Res. 2008 Oct 21;1236:185-93
references.pmid: 18710654
references.citation: Int J Oncol. 2009 Jun;34(6):1653-60
references.pmid: 19424584
references.citation: Int J Oncol. 2010 Apr;36(4):913-20
references.pmid: 20198336